Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PH-762

Oligonucleotide (siRNA) · Gene silencing: programmed cell death protein 1 (PDCD1) · developed by Phio Pharmaceuticals

Phase 1 Most advanced trial (none active)

PHIO Developer

1 Registered trials

What is PH-762?

PH-762 is a self-delivering siRNA targeting PD-1 (PDCD1) mRNA. Upon intratumoral administration, it prevents PD-1 expression, restoring T-cell activation and proliferation to mount a cytotoxic immune response against tumor cells. It is studied in skin cancers including melanoma, squamous cell carcinoma, and Merkel cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (siRNA)
Targets: programmed cell death protein 1 (PDCD1)
Mechanism: Gene silencing: programmed cell death protein 1 (PDCD1)
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Oncology
Developer: Phio Pharmaceuticals Inc. (PHIO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06014086	Phase 1	Squamous Cell Carcinoma of the Skin	Completed	PHIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Malignant Melanoma of SkinMerkel Cell Carcinoma of SkinSquamous Cell Carcinoma of the Skin

Other drugs acting on PDCD1

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CDX-585 Phase 1 CTX-8371 Phase 1 Geptanolimab Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the PHIO page.

Follow PHIO, the company behind PH-762

See PHIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PHIO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z